SPINEJACK®: a revolutionary implant to treat vertebral compression fractures
An European company with international presence (56% of turnover from exports at 31 December 2013)
2014 revenue: €10.3m
Winner of the 2012 NYSE Alternext prize
The specialist in innovative back micro-surgery
from the CEO
Dear Shareholders and Friends,
I am delighted with the results of our public offering succeeded in April 2012, all the more so as it took place in a very difficult market environment but in fact drew significant interest from the financial community due to its growth model, which is based on the SpineJack® innovation.
My sincere thanks to all those who contributed to the success of this listing, in particular our longstanding shareholders for their solid support, our new shareholders for their trust, and all our employees and partners.
This trust constitutes the foundation for Vexim’s next stage of development: dynamic, targeted commercialization on key European markets to establish SpineJack® as the standard treatment for vertebral compression fractures and Vexim as one of the leaders in the back pain market.
Vincent Gardès CEO
The intravertebral SpineJack®, implant is intended on the onehand to restore a collapsed vertebral body after a fracture, and on the other to maintain this restoration until a stabilizing material is injected to permanently immobilize it.
Cohesion® Bone Cement is a polymethyl methacrylate (PMMA) bone cement specially designed for treating complex VCFs. PMMA has unique properties that make it both versatile and tough.
MasterflowTM system is redefining cement delivery in vertebral augmentation.